Nineteen trials have been completed using Alpha GPC. It improved the recall and attention in a group of young males compared against a control group. In middle aged patients, it benefited reaction time, improved energy generation, and electrical coordination within the brain. It has also been studied in subjects with a moderate or severe brain damage exhibiting signs of dementia. Alpha GPC improved mood and cognitive processing.

In a trial of 2044 patients suffering from recent stroke or transient ischemic attack (TIA), Alpha GPC was administered 1000 mg IM for 28 days followed by 400 mg TID, for five months. Using a variety of mental tests, 71 percent of the patients saw benefits in cognitive recovery. In an 817 patient study with seniors affected by dementia, 79.2 percent of patients received a clinical response to Alpha GPC.

Alpha GPC has been compared with other brain nutrients such as Acetyl L carnitine and CDP choline and has performed better in clinical trials in the areas of mental focus, recall, verbal fluency and enhancement of mental performance. In clinical testing there have been no serious adverse reports. Less than one percent of those taking Alpha GPC have noticed digestive upset, skin reaction, or insomnia.

Health Concerns Cogni Spark Ingredients

Alpha-Glyceryl Phosphoryl Choline

Cogni-Spark is fast acting and results are typically seen in one to four weeks at the recommended dosage

 It is recommended that the last dose of the day be taken no later than 6PM to prevent insomnia